Skip to search formSkip to main contentSkip to account menu

velaglucerase alfa

Known as: EC 3.2.1.45, Human Glucosylceramidase (EC 3.2.1.45 or Beta-Glucocerebrosidase), Glycoform Alpha 
National Institutes of Health

Related topics

Related topics

5 relations
GLUCOSYLCERAMIDASEanalogs & derivativesimiglucerasevelaglucerase alfa 400 UNT Injection [Vpriv]

Narrower (1)

Vpriv

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
2018
2018
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
2016
2016
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
2016
2016
Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
2016
2016
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
2016
2016
Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
2014
2014
Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)